Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aurinia PharmaceuticalsAUPH +0.13%80 3-Year ROIIC % is 90.03 as of Dec. 2025, which is 42% below its 10-year median of 154.16. GuruFocus rates AUPH with a GF Score™ of 80/100 and a GF Value™ of $14.06 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,322 Biotechnology companies, Aurinia Pharmaceuticals ranks better than 77.46% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Aurinia Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 90.03%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Aurinia Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
AUPH's 3-Year ROIIC % is ranked better than 77.46% of 1322
companies
in the Biotechnology industry
Industry Median: -4.835
vs AUPH: 90.03
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Aurinia Pharmaceuticals 3-Year ROIIC % Related Terms
Aurinia Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AUPH vs KOD, ABCL, AGIO: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Aurinia Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurinia Pharmaceuticals 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's 3-Year ROIIC % falls into.
Aurinia Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 106.561 (Dec. 2025) - -111.47 (Dec. 2022) )
/
( 283.656 (Dec. 2025) - 41.48 (Dec. 2022) )
=
218.031
/
242.176
=
90.03%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Aurinia Pharmaceuticals (AUPH) has a 3-Year ROIIC % of 90.03 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Aurinia Pharmaceuticals and its competitors. This is 42% below median its historical median of 154.16. According to the industry distribution chart, Aurinia Pharmaceuticals ranks #298 out of 1322 companies in the Biotechnology industry, placing it in the top 22.5%.
Is Aurinia Pharmaceuticals' 3-Year ROIIC % too high?
Aurinia Pharmaceuticals' current 3-Year ROIIC % of 90.03 is 42% below median its 10-year median of 154.16. Based on the distribution chart, Aurinia Pharmaceuticals ranks #298 out of 1322 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aurinia Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' 3-Year ROIIC % compare to KOD and ABCL?
According to the Biotechnology industry distribution chart, Aurinia Pharmaceuticals ranks #298 out of 1322 companies for 3-Year ROIIC %. This places Aurinia Pharmaceuticals in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current 3-Year ROIIC % is 90.03, which is 42% below median its own 10-year median of 154.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.06, compared to a current price of $15.96 — trading 13.5% above its estimated fair value. The current 3-Year ROIIC % is 90.03, which is 42% below median its 10-year median of 154.16. Aurinia Pharmaceuticals' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current 3-Year ROIIC % is 90.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued.
The current stock price of $15.96 is trading 13.5% above its estimated GF Value™ of $14.06.
GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for AUPH:
3-Year ROIIC %: 90.03 (42% below median its 10-year median of 154.16)
GF Value™: $14.06 vs. price of $15.96 (13.5% above fair value)
No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
80GF Score
Get the complete analysis for AUPH
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AUPH has been successfully added to your 
